Optimizing GVHD Prophylaxis after Reduced-Intensity Matched Donor Transplantation in AML and MDS: Insights from PTCy and ATG Strategies
Posted inHematology-Oncology news

Optimizing GVHD Prophylaxis after Reduced-Intensity Matched Donor Transplantation in AML and MDS: Insights from PTCy and ATG Strategies

A large registry analysis supports post-transplant cyclophosphamide (PTCy) as an effective alternative to anti-thymocyte globulin (ATG) for preventing graft-versus-host disease (GVHD) in reduced-intensity conditioning matched donor peripheral blood stem cell transplantation for AML and MDS.
Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCT
Posted inHematology-Oncology news Oncology

Unified Conditioning and GVHD Prophylaxis with Fludarabine, Cyclophosphamide, and 2 Gy TBI plus Post-Transplant Cyclophosphamide in Elderly AML/MDS Patients Undergoing Haploidentical or Unrelated Donor Allo-SCT

Fludarabine, cyclophosphamide, and low-dose TBI combined with post-transplant cyclophosphamide provide a safe and effective single platform for haploidentical and unrelated donor allo-SCT in older AML/MDS patients, showing favorable survival and GVHD outcomes.
Allogeneic HCT Rebounds, PTCy Reshapes Donor Choice, and CAR‑T Use Surges: Key Trends from the 2013–2023 CIBMTR Activity Report
Posted inHematology-Oncology news

Allogeneic HCT Rebounds, PTCy Reshapes Donor Choice, and CAR‑T Use Surges: Key Trends from the 2013–2023 CIBMTR Activity Report

CIBMTR's 2013–2023 registry update shows a 2023 rebound in allogeneic HCT—driven by older adults—widespread adoption of post‑transplant cyclophosphamide (PTCy) across donor types, increasing mismatched donor use, and rapid expansion of commercial CAR‑T therapy; relapse remains the leading cause of death.